KẾT QUẢ ĐIỀU TRỊ BỆNH VÕNG MẠC TRẺ ĐẺ NON BẰNG TIÊM BEVACIZUMAB NỘI NHÃN SAU 5 NĂM TẠI BỆNH VIỆN NHI TRUNG ƯƠNG

Abstract

Objective: Assess the outcomes of intravitreal Bevacizumab therapy for retinopathy of prematurity over five years at the National Children’s Hospital. Materials and methods: the study was conducted on patients diagnosed with retinopathy of prematurity type 1 who underwent intravitreal Bevacizumab injection at the Department of Ophthalmology – National Children’s Hospital before February 2018. This retrospective cross-sectional descriptive study encompasses 224 eyes of 115 patients. Results: Following treatment, 177 eyes had complete regression, comprising 79% of the total, while 47 eyes exhibited incomplete regression, accounting for 21%, with 1,3% experiencing retinal detachment. 185 eyes had best-corrected visual acuity (BCVA) of more than 5/10 (82,6%), while 39 eyes had BCVA less than 5/10 (17,4%), and three eyes had BCVA only counting fingers at 3 meters. Amblyopia was observed in 43 eyes (29,3%), while strabismus affected 25,2% (29/115 patients). Conclusion: The outcomes of Bevacizumab treatment for retinopathy of prematurity over five years are encouraging, with 79% of affected eyes achieving complete regression post-treatment, and 82,6% attaining normal BCVA.